An Adaptive Design for Phase II Non-Oncology Dose Selection Clinical Trials

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.30, Iss.6, 2010-06, pp. : 397-403

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Group-Sequential Methods for Adaptive Seamless Phase II/III Clinical Trials

By Stallard Nigel

Journal of Biopharmaceutical Statistics, Vol. 21, Iss. 4, 2011-07 ,pp. : 787-801

Taylor & Francis Ltd

Access to resources Recommend Favorite

Adaptive Bayesian Design for Phase I Dose-Finding Trials Using a Joint Model of Response and Toxicity

By Wang Meihua

Journal of Biopharmaceutical Statistics, Vol. 20, Iss. 1, 2010-01 ,pp. : 125-144

Taylor & Francis Ltd

Access to resources Recommend Favorite

Randomized Phase II Clinical Trials

Journal of Biopharmaceutical Statistics, Vol. 24, Iss. 4, 2014-07 ,pp. : 802-816

Taylor & Francis Ltd

Access to resources Recommend Favorite

The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria

Cancer, Vol. 120, Iss. 24, 2014-12 ,pp. : 3853-3858

Blackwell Publishing

Access to resources Recommend Favorite

Current Issues in Oncology Drug Development, with a Focus on Phase II Trials

By Sargent Daniel

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 3, 2009-05 ,pp. : 556-562

Taylor & Francis Ltd

Access to resources Recommend Favorite